Display options
Cite
Armstrong GT, Ross JD. Late Cardiotoxicity in Aging Adult Survivors of Childhood Cancer. Prog Pediatr Cardiol. 2014;36(1):19-26doi: 10.1016/j.ppedcard.2014.09.003.
Armstrong, G. T., & Ross, J. D. (2014). Late Cardiotoxicity in Aging Adult Survivors of Childhood Cancer. Progress in pediatric cardiology, 36(1), 19-26. https://doi.org/10.1016/j.ppedcard.2014.09.003
Armstrong, Gregory T, and Ross, Jordan D. "Late Cardiotoxicity in Aging Adult Survivors of Childhood Cancer." Progress in pediatric cardiology vol. 36,1 (2014): 19-26. doi: https://doi.org/10.1016/j.ppedcard.2014.09.003
Armstrong GT, Ross JD. Late Cardiotoxicity in Aging Adult Survivors of Childhood Cancer. Prog Pediatr Cardiol. 2014 Sep 01;36(1):19-26. doi: 10.1016/j.ppedcard.2014.09.003. PMID: 26412958; PMCID: PMC4580976.
Copy Download .nbib Format: NLM
Share it on

Prog Pediatr Cardiol. 2014 Sep 01;36(1):19-26. doi: 10.1016/j.ppedcard.2014.09.003.

Late Cardiotoxicity in Aging Adult Survivors of Childhood Cancer.

Progress in pediatric cardiology

Gregory T Armstrong, Jordan D Ross

Affiliations

  1. St. Jude Children's Research Hospital.
  2. The University of Tennessee Health Science Center College of Medicine.

PMID: 26412958 PMCID: PMC4580976 DOI: 10.1016/j.ppedcard.2014.09.003

Abstract

The survival rate for childhood cancer is steadily improving, and the current estimate for the prevalence of childhood cancer survivors in the United States is 420,000. With this encouraging trend and the aging of this population, there is an ever-increasing responsibility to identify adult survivors of childhood cancer with adverse health outcomes related to cancer treatment across the span of their lives. To accomplish this, large cohort studies have been developed to follow survivors longitudinally. Compared to siblings, survivors have a higher cumulative incidence of morbidity and mortality, and this gap in incidence only widens with age. One of the most significant late toxicities in survivors is late onset cardiotoxicity, largely due to anthracycline and chest-directed radiation exposure. Survivors also have an increased prevalence of traditional cardiovascular risk factors as they age, which potentiates the risk for major cardiac events. Prevention is essential. Minimizing anthracycline dose exposure in pediatric cancer patients is a primary method of cardioprotection. Dexrazoxane and enalapril have also been studied as primary (pre-exposure) and secondary (post-exposure) cardioprotecant agents, respectively. Additionally, the Children's Oncology Group has published exposure-driven, risk-based screening guidelines for long-term follow-up, which may be a cost-effective way to identify subclinical cardiac disease before progression to clinical presentation. Ongoing research is needed to determine the most effective diagnostic modality for screening (e.g. echocardiography), and the most effective intervention strategies to improve long-term outcomes.

Keywords: Anthracycline; cardiomyopathy; cardioprotection; intervention; screening

References

  1. J Pediatr Hematol Oncol. 2010 Apr;32(3):171-9 - PubMed
  2. J Clin Oncol. 2014 Apr 20;32(12):1218-27 - PubMed
  3. J Clin Oncol. 2009 May 10;27(14):2363-73 - PubMed
  4. Ann Intern Med. 2014 May 20;160(10 ):731-2 - PubMed
  5. Eur J Cancer. 2013 Feb;49(3):668-75 - PubMed
  6. J Clin Oncol. 2012 Apr 1;30(10 ):1050-7 - PubMed
  7. J Clin Oncol. 2009 May 10;27(14):2319-27 - PubMed
  8. Future Cardiol. 2012 Jul;8(4):647-70 - PubMed
  9. J Clin Oncol. 2002 Dec 1;20(23):4517-22 - PubMed
  10. J Cancer Surviv. 2013 Sep;7(3):379-91 - PubMed
  11. J Adolesc Young Adult Oncol. 2011 Dec;1(4):188-194 - PubMed
  12. Pediatr Blood Cancer. 2013 Nov 6;:null - PubMed
  13. Nat Rev Cancer. 2014 Jan;14 (1):61-70 - PubMed
  14. Intern Emerg Med. 2014 Jun;9(4):359-64 - PubMed
  15. Int J Pediatr. 2011;2011:461512 - PubMed
  16. JAMA. 2013 Jun 12;309(22):2371-81 - PubMed
  17. J Clin Oncol. 2004 Mar 1;22(5):820-8 - PubMed
  18. J Clin Oncol. 2012 Aug 10;30(23):2876-84 - PubMed
  19. J Nucl Cardiol. 2013 Jun;20(3):443-64 - PubMed
  20. Blood. 2012 Nov 29;120(23):4505-12 - PubMed
  21. Cochrane Database Syst Rev. 2013 Apr 30;(4):CD008796 - PubMed
  22. J Clin Oncol. 2012 Dec 10;30(35):4401-8 - PubMed
  23. J Cancer Surviv. 2013 Dec;7(4):523-34 - PubMed
  24. Lancet Oncol. 2010 Oct;11(10 ):950-61 - PubMed
  25. Ann Intern Med. 2010 Apr 6;152(7):409-17, W131-8 - PubMed
  26. J Natl Cancer Inst. 2010 Jan 6;102(1):14-25 - PubMed
  27. Diabetes Metab Res Rev. 2010 Feb;26(2):121-7 - PubMed
  28. J Clin Oncol. 2012 May 1;30(13):1429-37 - PubMed
  29. Cancer Causes Control. 2013 Feb;24(2):313-21 - PubMed
  30. Pediatr Blood Cancer. 2013 Mar;60(3):351-6 - PubMed
  31. Ann Intern Med. 2014 May 20;160(10 ):672-83 - PubMed
  32. Ann Intern Med. 2014 May 20;160(10 ):661-71 - PubMed
  33. J Am Coll Cardiol. 2014 Jul 1;63(25 Pt A):2751-68 - PubMed
  34. J Clin Oncol. 2009 May 10;27(14):2328-38 - PubMed
  35. Eur J Pediatr. 2013 Sep;172(9):1149-60 - PubMed
  36. J Clin Oncol. 2009 May 10;27(14):2308-18 - PubMed
  37. BMJ. 2009 Dec 08;339:b4606 - PubMed
  38. J Clin Oncol. 2005 Apr 20;23(12):2629-36 - PubMed
  39. Pediatr Blood Cancer. 2012 May;58(5):752-7 - PubMed
  40. J Clin Oncol. 2013 Oct 10;31(29):3673-80 - PubMed

Publication Types

Grant support